Norero C, Delucchi A, Lagos E, Rosati P
Grupo Cooperativo Chileno de Estudio de Sindrome Nefrósico del Niño, Hospitale, Calvo.
Rev Med Chil. 1996 May;124(5):567-72.
Ninety six patients aged from 6 months to 15 years and were admitted to Chilean hospitals with the diagnosis of primary nephrotic syndrome in a period of 30 months. These patients were randomly separated in two groups, group A received prednisone for 8 weeks and group B received the same drug during 12 weeks. All patients were evaluated at 6, 12 and 18 months after the end of treatment. The moment and number of relapses per patient, accumulated percentage of relapses, relapse rate per 100 patients, total number of relapses and complications were assessed. Frequent relapsers were subjected to a kidney biopsy, leaving in the protocol only those patients that had minimal changes. Patients resistant or dependent to steroid therapy were discarded. Thus we report the results of 56 treated patients followed during 18 months. No differences in analyzed parameters were observed between the two treatment groups. It is concluded that these preliminary results do not support the prolongation of prednisone treatment in children with primary nephrotic syndrome.
96例年龄在6个月至15岁之间的患者在30个月的时间里被智利医院收治,诊断为原发性肾病综合征。这些患者被随机分为两组,A组接受泼尼松治疗8周,B组接受相同药物治疗12周。所有患者在治疗结束后的6个月、12个月和18个月进行评估。评估每位患者的复发时间和次数、复发累积百分比、每100例患者的复发率、复发总数及并发症情况。频繁复发者接受肾活检,方案中仅保留那些病变轻微的患者。对类固醇治疗耐药或依赖的患者被排除。因此,我们报告了56例接受治疗的患者在18个月内的随访结果。两个治疗组之间在分析参数上未观察到差异。结论是,这些初步结果不支持延长原发性肾病综合征患儿的泼尼松治疗时间。